Jack Matten

are you still seeing a better trend on a statutory margin basis?

Is that limit something you're still evaluating? Or could it be revised higher over time?

can you just talk about your outlook for that asset class and what kind of experience Aflac is being in its portfolio?

To what degree are you now like assuming future improvement in cancer and hospitalization trends, I guess, versus maybe your prior assumption

given that, should we be thinking about any kind of change in your assumptions as part of the unlocking next quarter?

can you just remind us where Aflac might be interested in terms of potential M&A, something to accelerate growth in the U.S. group

can you talk about competitive dynamics there and how you see the outlook for sales of your medical product?

Can you talk about what you're seeing so far in the uplift of sales you saw this quarter? I know the launch in stages

Could you just talk a little bit more about trends in that market and how you expect things to develop on Aflac's portfolio in 2025?

are there any kind of other launches or refreshes that you have planned this year that could impact the cadence of sales in 2025?

can you talk about what you're seeing in terms of consumer behavior? Is this more kind of macro-driven affordability issues or anything related to distribution?

any way you could maybe unpack or quantify some of those benefits you expect over time, whether it's on the expense ratio or for productivity?

does that include any assumption or any incorporation of a benefit from the Bermuda entity?

is there anything you're seeing or hearing from customers that's driving more muted sales growth in recent quarters? Or is the challenge really around agent productivity given that you currently ha...

The first one, the higher earnings guidance for this year. I guess how should we think about that translating to stat earnings and cash flows looking ahead to next year.

On the $200 million, I think, potential incremental benefits to your cash flows over time. I guess just any thoughts on like the time line towards getting to that run rate.

you recorded a smaller measurement gain even though, I guess, reported margins for the segment were a little bit weaker year-over-year basis

How much of a lag usually between kind of the rate actions you've taken and when do you usually see the benefit flow into your results?

Is there something in particular that's driving the improved outlook now versus what you had for me out of that ratio?

Were you able to quantify the different elements of that across the reinsurance accounting changes, and maybe the favorable underlying results

Any other code you can provide on that? Did you sell your subrogation rights? Or is there the potential for additional recoveries

It's not made a plan to recoup any of that with rate increases or supplemental fees

do you have any visibility at this point to kind of the cadence of realizations

could you just unpack some of the drivers there? And which do you think are kind of more repeated more sustainable versus some of the more transitory factors

the management fee rate in the quarter was, you know, 28.4, which is a bit lower than where you had been running

Any leading indicators around RFP volumes or anything else you can share regarding that outlook?

Is there anything notably that you'd call that's driving that and how you would expect that to trend over the near term?

I'm just wondering if you would expect to continue seeing strong margin expansion kind of in line with the 180 basis points this quarter with market performance remains strong

I'm just wondering if there's anything notable that's benefiting your margins in those lines. Then are you seeing pricing competition for your nondental lines of business getting more intense recen...

could we see potential upside if if market performance remains strong?

just wondering if you expect any near-term kind of headwinds from market volatility any other color on the outlook for that market?

On a forward-looking basis, would you expect less of an impact from those drivers?

I guess if you adjust for those 2 things, was there any change at all to the growth outlook?

a follow-up on the investment management net cash flows. It seems like deposits are pretty healthy, but withdrawals continue to be somewhat elevated

Wondering how you view the outlook both for you and for the industry regarding volumes this year

can you talk about the outlook for the private markets business and some of the investments that you referenced earlier

Your core earnings growth there took a nice step up this quarter. It looks like at least part of that was on kind of better spread earnings

could you just talk about any kind of expense efficiencies that you're driving across the organization

in the past month or so we've seen the yen weaken again and rate have been rising

A question on whether there's been any update or change to your thoughts around risk transfer, especially for the runoff VA business

premium growth in the quarter was pretty strong, kind of well above like the intermediate term target you've laid out. Just any color on what drove that result

do you think about the $3.5 billion this quarter is things that you can sustained throughout the balance of the year

are those comments related to GAAP earnings or are you referring to the cash flow conversion ratio

is that outlook assuming that products remain to raise normalize off of the more recent kind of elevated levels